Interferon-β1a-Induced Thrombotic Microangiopathy: Possible Implication of the Alternative Pathway of the Complement-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Interferon-β1a-Induced Thrombotic Microangiopathy: Possible Implication of the Alternative Pathway of the Complement

Published:2022-08 Issue:8 Volume:7 Page:1917-1921
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Taghavi Maxime^ORCID,Stordeur Patrick,Collart Frédéric,Dachy Bernard,Pozdzik Agnieszka,Mesquita Maria Do Carmo Filomena,Nortier Joëlle

Publisher

Elsevier BV

Subject

Nephrology

Reference9 articles.

1. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference;Goodship;Kidney Int,2017

2. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015;Noris;Am J Kidney Dis,2015

3. A case report of late-onset atypical hemolytic uremic syndrome during interferon beta in multiple sclerosis: open issues in literature review;Parisi;Brain Behav,2021

4. After the party’s over;George;N Engl J Med,2017

5. Endothelial cell functions impaired by interferon in vitro: insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy;Jia;Thromb Res,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18

2. Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment—A Literature Review;Journal of Clinical Medicine;2024-03-11

3. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management;Frontiers in Pharmacology;2023-01-09

4. Cefuroxime/interferon beta 1a;Reactions Weekly;2022-09-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3